
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
By optimizing formulation and process varibles, pellets can be prepared that can release a poorly soluble drug for 12-24 h following zero-order kinetics.
almost 25 years ago
Using Earned-Value Analysis to Better Manage Projectsalmost 25 years ago
Microbial Bioburden on Oral Solid Dosage Formsalmost 25 years ago
Modernizing Pharmaceutical Manufacturingalmost 25 years ago
The Role of Computational Fluid Dynamics in the Pharmaceutical Industryalmost 25 years ago
Outsourcing Outlook





